A systematic review of the current literature on the efficacy of baclofen, particularly the effect
of dosing, for the treatment of alcohol dependence (AD) is missing. We therefore conducted …

Background Alcohol use disorder (AUD) and alcohol‐related impairments belong to the
most widespread psychiatric disorders leading to specific psychophysical, affective and …

Patients who suffer from alcohol use disorders (AUDs) usually go through various socio-
behavioral and pathophysiological changes that take place in the brain and other organs …

Baclofen, β-(4-chlorophenyl)-γ-aminobutyric acid, holds a unique position in neuroscience,
remaining the only US Food and Drug Administration (FDA) approved GABAB agonist …

Alcohol use disorder (AUD) is a brain disorder associated with high rates of mortality and
morbidity worldwide. Baclofen, a selective gamma-aminobutyric acid-B (GABA-B) receptor …

Compounds known to be successful in the treatment of alcohol use disorder include the
aversive agent, Disulfiram, the glutamatergic NMDA receptor antagonist, Acamprosate, and …

Context: Prescriptions for nonopioid pharmacological therapies such as gabapentin and
baclofen have been increasing. While gabapentin and baclofen are less likely than opioids …

Baclofen toxicity results from intentional self-poisoning (acute baclofen poisoning) or
accumulation of therapeutic dose in the setting of impaired kidney function. Standard care …

For more than 25 years, researchers have made advances in developing medications to
treat alcohol use disorder (AUD), highlighted by the US Food and Drug Administration's …

Background Alcohol use disorder (AUD) is one of the most widespread psychiatric disorders
leading to detrimental consequences to people with this disorder and others. Worldwide, the …